dm+d

Unassigned

New Medicines

Angiosarcoma - in combination with pazopanib

Information

New molecular entity
TRACON Pharmaceuticals
TRACON Pharmaceuticals

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Yes
Yes
Apr 19Development discontinued [10].
Apr 19PIII TAPPAS trial in patients with advanced or metastatic angiosarcoma was terminated for futility, following interim analysis of data in 120 patients [9].

Category

ENG protein inhibitor, suppressing angiogenesis
Angiosarcoma is a rare cancer: it accounts for about 4% of soft tissue sarcomas, which are themselves rare (UK age-standardised incidence for 2010 about 45 per million or 3272 cases). It is an aggressive cancer with a high local recurrence rate and metastasis; reported five-year survival is around 20%
Angiosarcoma - in combination with pazopanib
Intravenous infusion

Further information

Yes

Evidence based evaluations